Global Atrial Fibrillation Market - 2023-2030

Market Overview

The Global Atrial Fibrillation Market reached US$ 19.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 42.8 billion by 2030. The Global Atrial Fibrillation Market is expected to exhibit a CAGR of 10.7% during the forecast period 2023-2030.

Atrial fibrillation (A-fib) is an arrhythmia (an irregular and typically very fast heart rhythm) that can result in blood clots in the heart. Stroke, heart failure, and other heart-related problems are all increased by atrial fibrillation.

During atrial fibrillation, the heart's top chambers (the atria) beat chaotically and irregularly, out of rhythm with the bottom chambers (the ventricles). Many persons with atrial fibrillation have no symptoms. Atrial fibrillation, conversely, can induce a rapid, hammering heartbeat (palpitations), shortness of breath, or weakness.

Market Dynamics

The Rising Burden of Obesity and Heart Diseases Drives the Market Growth

The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality around the world, and due to the changing lifestyle, the number of people suffering from heart diseases is proliferating. Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD).

The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue can induce cardiac dysfunction and promote the formation of atherosclerotic plaques.

Lack of Strategies to Effectively Treat Atrial Fibrillation

The absence of a thorough knowledge of the pathogenesis of atrial fibrillation, as well as the inefficiency and adverse effects associated with antiarrhythmic medication therapy, pose significant obstacles in treating atrial fibrillation.

The expanding number of patients with atrial fibrillation and the growing need to adapt treatment options such as anticoagulation, antiarrhythmic medicines, and rate control medications is increasing the normal health care system load. Furthermore, a lack of awareness and understanding concerning atrial fibrillation and potential therapeutic techniques is slowing the uptake of atrial fibrillation therapy devices and procedures.

COVID-19 Impact Analysis

The influence of COVID-19 on atrial fibrillation was enormous; according to a comprehensive study, the incidence of atrial fibrillation was 8% of COVID-19 patients and was related to older age, male sex, and hypertension. Patients with Atrial Fibrillation had a greater risk of all-cause death than those who did not have atrial fibrillation. Similar results were seen in patients with newly diagnosed atrial fibrillation.

The findings highlight the negative effect of atrial fibrillation in COVID-19 patients and support the necessity for developing unique and targeted measures for the prevention, diagnosis, and therapy of COVID-19 patients with concurrent AF. More research is needed to determine the best ways to monitor these individuals, particularly antithrombotic treatments.

Segment Analysis

The Global Atrial Fibrillation Market is segmented based on treatment type and end user.

The Ambulatory Surgical Center Segment is Expected to Grow During the Forecast Period

The ambulatory surgical center segment is expected to witness good growth of around 33.3% due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases like atherosclerosis and heart failure are expected to propel the market.

However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, encourage patients to opt for minimally invasive surgeries, which is expected to boost market growth.

Geographical Analysis

North America is the dominating region during the forecast period.

The North American region is expected to dominate the atrial fibrillation market and account for around 41.5% in the forecast period. This is majorly attributed to the rising patient pool in the region and the presence of key players.

The North American region is predicted to lead the worldwide atrial fibrillation market due to the growing acceptance of technologically sophisticated devices and a significant increase in cardiac problems among the aging and general population.

Furthermore, a well-established healthcare infrastructure is projected to support the market's long-term expansion in North America. During the projection period, the North American atrial fibrillation market benefit from patient's high disposable income and growing fibrillation prevalence.

Competitive Landscape

The major global players include: AtriCure, Biosense Webster, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, Cardio Focus, Endoscopic Technologies, Sanofi Aventis, Abbott, Johnson and Johnson.

Why Purchase the Report?

• To visualize the Global Atrial Fibrillation Market segmentation based on the treatment type, end user and region, and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous atrial fibrillation market level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Atrial Fibrillation Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies